1. Academic Validation
  2. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors

A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors

  • J Med Chem. 2001 Mar 15;44(6):851-6. doi: 10.1021/jm000494a.
J A Robl 1 R Sulsky C Q Sun L M Simpkins T Wang J K Dickson Jr Y Chen D R Magnin P Taunk W A Slusarchyk S A Biller S J Lan F Connolly L K Kunselman T Sabrah H Jamil D Gordon T W Harrity J R Wetterau
Affiliations

Affiliation

  • 1 The Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, USA. Jeffrey.Robl@bms.com
Abstract

A series of benzimidazole-based analogues of the potent MTP inhibitor BMS-201038 were discovered. Incorporation of an unsubstituted benzimidazole moiety in place of a piperidine group afforded potent inhibitors of MTP in vitro which were weakly active in vivo. Appropriate substitution on the benzimidazole ring, especially with small alkyl groups, led to dramatic increases in potency, both in a cellular assay of apoB secretion and especially in animal models of Cholesterol lowering. The most potent in this series, 3g (BMS-212122), was significantly more potent than BMS-201038 in reducing plasma lipids (Cholesterol, VLDL/LDL, TG) in both hamsters and cynomolgus monkeys.

Figures